{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T16:35:38Z","timestamp":1749227738567},"reference-count":27,"publisher":"Korean Cancer Association","issue":"1","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2023,1,15]]},"abstract":"<jats:p>Purpose High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin\u2019s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.Materials and Methods Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg\/kg\/day, intravenously) administered on days \u20137, \u20136, and \u20135, etoposide (400 mg\/m&lt;sup&gt;2&lt;\/sup&gt; intravenously) on days \u20135 and \u20134, and melphalan (50 mg\/m2\/day intravenously) on days \u20133 and \u20132. The BuCE regimen was comprised of busulfan (3.2 mg\/kg\/day intravenously) on days \u20137, \u20136, and \u20135, etoposide (400 mg\/m&lt;sup&gt;2&lt;\/sup&gt;\/day intravenously) on days \u20135 and \u20134, and cyclophosphamide (50 mg\/kg\/day intravenously) on days \u20133 and \u20132. The primary endpoint was 2-year progression-free survival (PFS).Results Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.Conclusion There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.<\/jats:p>","DOI":"10.4143\/crt.2022.004","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:38:37Z","timestamp":1648604317000},"page":"304-313","update-policy":"http:\/\/dx.doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin\u2019s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)"],"prefix":"10.4143","volume":"55","author":[{"given":"Kyoung Ha","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon-Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moo-Rim","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Yong","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeung-Chul","family":"Mun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ho","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199512073332305"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1995.13.3.588"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702795"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v77.7.1587.bloodjournal7771587"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705841"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1185785"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705175"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00687.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.01.002"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13664"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1988.6.10.1562"},{"key":"ref12","first-page":"1244","volume-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","author":"Cheson","year":"1999"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0196-3"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15713"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.240"},{"key":"ref16","first-page":"133","volume-title":"Preparation for marrow transplantation in Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma using Bu\/CY","author":"Avalos","year":"1993"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702433"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218652"},{"key":"ref20","first-page":"2279","volume-title":"Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation","author":"Jagadeesh","year":"2020"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.45.9453"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04309-7"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02999-9"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0382-1"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804980"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2022-004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2022.004","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2022-004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T01:15:53Z","timestamp":1673486153000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2022.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2022.004","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]},"assertion":[{"value":"2022-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}